Vaxart Inc logo

VXRT

Vaxart Inc

$3.94

Earnings Summary

Revenue
$0.09Mn
Net Profits
$-25.1Mn
Net Profit Margins
-29530.59%

Highlights

Revenue:

Vaxart Inc’s revenue fell -83.2% since last year same period to $0.09Mn in the Q1 2022. On a quarterly growth basis, Vaxart Inc has generated 14.86% jump in its revenue since last 3-months.

Net Profits:

Vaxart Inc’s net profit fell -56.81% since last year same period to $-25.1Mn in the Q1 2022. On a quarterly growth basis, Vaxart Inc has generated -20.89% fall in its net profits since last 3-months.

Net Profit Margins:

Vaxart Inc’s net profit margin fell -833.5% since last year same period to -29530.59% in the Q1 2022. On a quarterly growth basis, Vaxart Inc has generated -5.24% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Vaxart Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.21
EPS Estimate Current Year
-0.21

Highlights

EPS Estimate Current Quarter:

Vaxart Inc’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a -31.25% fall from last quarter’s estimates.

EPS Estimate Current Year:

Vaxart Inc’s earning per share (EPS) estimates for the current year stand at -0.21.

Key Ratios

Key ratios of the Vaxart Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.2
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.45
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Vaxart Inc’s earning per share (EPS) fell -42.86% since last year same period to -0.2 in the Q1 2022. This indicates that the Vaxart Inc has generated -42.86% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Vaxart Inc’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Vaxart Inc’s return on equity (ROE) stands at -0.45.

Dividend Per Share (DPS):

Vaxart Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.16
-0.2
-25%

Company Information

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Organisation
Vaxart Inc
Employees
28
Industry
Health Technology